Andrea Brettler

The discontinuation of Celgene Corporation (NASDAQ: CELG)’s mongerson for Crohn’s disease prompted a 6.6-percent sell-off in Friday’s premarket trading. But UBS was undeterred by the announcement. “Looking forward, we are still encouraged by the prospects for this next...